BC
TGTX icon

Bartlett & Co’s TG Therapeutics TGTX Stock Holding History

Bartlett & Co’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		$441K Hold
25,000
– – 0.01% 365
2023
Q3 		$209K Hold
25,000
– – ﹤0.01% 438
2023
Q2 		$621K Hold
25,000
– – 0.01% 314
2023
Q1 		$376K Hold
25,000
– – 0.01% 311
2022
Q4 		$296K Hold
25,000
– – 0.01% 344
2022
Q3 		$148K Buy
+25,000
New +$164K ﹤0.01% 411

Other funds holding TGTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Bartlett & Co's TGTX Position: Q4 2023 in Review

Bartlett & Co held its TG Therapeutics (TGTX) position steady in Q4 2023 at 25,000 shares worth $441K. The position accounts for 0.01% of the portfolio, ranked #365.

Bartlett & Co first reported a position in TGTX in Q3 2022 and has held it in 6 quarters since. The position peaked at $621K in Q2 2023. 235 funds tracked by Wall St. Rank hold TGTX as of Q4 2023.

  • Bartlett & Co held 25,000 shares of TG Therapeutics worth $441K as of Q4 2023.
  • Bartlett & Co left its TG Therapeutics share count unchanged in Q4 2023.
  • TG Therapeutics made up 0.01% of Bartlett & Co's portfolio in Q4 2023, its #365 holding.
  • Bartlett & Co first reported a position in TG Therapeutics in Q3 2022 and has held it in 6 quarters since.
  • Bartlett & Co's TG Therapeutics position peaked at $621K in Q2 2023.
  • 235 funds tracked by Wall St. Rank held TG Therapeutics as of Q4 2023.

Based on Bartlett & Co's 13F filing for Q4 2023, filed 8 Jan 2024.